Company profile
RBC Life Sciences, Inc.
OTC: RBCL · Consumer Defensive · Household & Personal Products
#197 of 386 Consumer Defensive companies by revenue59th-percentile growth
EA Score
——FH —DQ —GM —SS 43
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, listing tenure · ↓ Piotroski F, market scale
Methodology →Revenue TTM
$23.6M
Rev growth YoY (TTM)
-9.0%
Net income (FY)
-$756.3k
Employees
89
as of 2026-08-31
Market cap
$1.5k
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$25.8M$25.8M2016
Net income-$756.3k-$756.3k2016
Operating income-$666.3k-$666.3k2016
Total assets$11.0M$11.0M2016
Liabilities$3.8M$3.8M2016
Equity$7.1M$7.1M2016
Revenue trend
FY2009 – FY2016 · USD
FY09
FY10
FY11
FY12
FY13
FY14
FY15
FY16
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is RBC Life Sciences, Inc.’s revenue?
RBC Life Sciences, Inc. booked $25.8M in FY2016 revenue, growing 5.8% year over year — about the middle of the pack among Consumer Defensive companies we track, at a -2.9% net margin.
Neighbors
Dallas →Key facts
CEODavid Price
SectorConsumer Defensive
IndustryHousehold & Personal Products
HeadquartersIrving, TX
ExchangeOTC: RBCL
Employees89
IPO date2000-01-03
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.